Trial Profile
Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Selicrelumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Proof of concept
- Acronyms CITN11-01
- 10 Jun 2021 Results published in the Clinical Cancer Research
- 12 Apr 2019 Status changed from recruiting to completed.
- 08 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov reccord.